Adaptin Bio (APTN) Accumulated Expenses (2024 - 2026)

Adaptin Bio (APTN) has 3 years of Accumulated Expenses data on file, last reported at $869681.0 in Q1 2026.

• For the quarter ending Q1 2026, Accumulated Expenses rose 11.26% year-over-year to $869681.0; the trailing twelve-month figure through Mar 2026 stood at $869681.0 (up 11.26% YoY), and the FY2025 full-year result was $596465.0, up 342.24% from the prior year.
• Accumulated Expenses advanced to $869681.0 in Q1 2026, from $596465.0 in the prior quarter.
• In the past five years, Accumulated Expenses ranged from a high of $869681.0 in Q1 2026 to a low of $134875.0 in Q4 2024.
• A 3-year average of $571139.3 and a median of $559470.5 in 2025 frame the typical range for Accumulated Expenses.
• Across the five-year window, Accumulated Expenses soared 342.24% in 2025 and gained 11.26% in 2026, its largest moves.
• Tracing APTN's Accumulated Expenses over 3 years: stood at $134875.0 in 2024, then jumped by 342.24% to $596465.0 in 2025, then surged by 45.81% to $869681.0 in 2026.
• Business Quant data shows APTN's Accumulated Expenses at $869681.0 in Q1 2026, $596465.0 in Q4 2025, and $522476.0 in Q3 2025.